868387-45-5

Basic information

• Product Name: tert-Butyl (4-bromothiophen-2-yl)carbamate
• Synonyms: tert-Butyl (4-bromothiophen-2-yl)carbamate;1,1-diMethylethyl (4-broMo-2-thienyl)carbaMate tert-butyl 4-broMothiophen-2-ylcarbaMate;2-(Boc-aMino)-4-broMothiophene;tert-Butyl (4-broMo-2-thienyl)carbaMate;N-(4-BroMo-2-thienyl)-carbaMic Acid 1,1-DiMethylethyl Ester;tert-butyl N-(4-bromothiophen-2-yl)carbamate;tert-Butyl (4-bromothiophen-2-yl)
• CAS NO: 868387-45-5
• Molecular Formula: C₉H₁₂BrNO₂S
• Molecular Weight: 278.169
• Mol File: 868387-45-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 279℃
• Flash Point: 123℃
• Appearance: /
• Density: 1.510
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.96±0.70(Predicted)
• CAS DataBase Reference: tert-Butyl (4-bromothiophen-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl (4-bromothiophen-2-yl)carbamate(868387-45-5)
• EPA Substance Registry System: tert-Butyl (4-bromothiophen-2-yl)carbamate(868387-45-5)

Safety Data

• Hazardous Substances Data: 868387-45-5(Hazardous Substances Data)

Usage

Description

tert-Butyl (4-bromothiophen-2-yl)carbamate, also known as N-(4-bromo-2-thienyl)-carbamic Acid 1,1-Dimethylethyl Ester, is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by its carbamate functional group and a 4-bromothiophen-2-yl moiety, which contributes to its reactivity and potential applications in chemical synthesis.

Uses

Used in Pharmaceutical Industry:
tert-Butyl (4-bromothiophen-2-yl)carbamate is used as an intermediate in the synthesis of bicyclic inhibitors of ROCK protein kinases for the development of potential therapeutic agents. These inhibitors can modulate cellular signaling pathways and have potential applications in the treatment of various diseases, including cancer and neurological disorders.
Used in Chemical Synthesis:
In the field of chemical synthesis, tert-Butyl (4-bromothiophen-2-yl)carbamate is utilized as a building block for the preparation of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure and reactivity make it a valuable component in the synthesis of complex molecules with diverse applications.

InChI:InChI=1/C9H12BrNO2S/c1-9(2,3)13-8(12)11-7-4-6(10)5-14-7/h4-5H,1-3H3,(H,11,12)

Upstream product

• 16694-18-1 4-bromo-thiophene-2-carboxylic acid 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 1163729-45-0 4-bromothiophen-2-amine 
• 943321-78-6 1,1-dimethylethyl {4-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-2-thienyl}carbamate 
• 943321-42-4 1,1-dimethylethyl {4-[1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-2-thienyl}carbamate 
• 868387-46-6 tert-butyl 4-(1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)thiophen-2-ylcarbamate 

Relevant articles and documents

4-PHENYL-N-(PHENYL)THIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS

4-phenyl-N-(phenyl)thiazol-2-amine and 4-(pyridin-3-yl)-N-( phenyl) thiazol-2-amine derivatives and the corresponding thiadiazole, thiophene, oxazole, oxadiazole, imidazole and triazole derivatives and related compounds as aryl hydrocarbon receptor (AHR) agonists for the treatment of angiogenesis implicated disorders, such as e.g. retinopathy, psoriasis, rheumatoid arthritis, obesity and cancer, or inflammatory disorders.

Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors

The Rho kinases (ROCK1 and ROCK2) are highly homologous serine/threonine kinases that act on substrates associated with cellular motility, morphology, and contraction and are of therapeutic interest in diseases associated with cellular migration and contraction, such as hypertension, glaucoma, and erectile dysfunction. Beginning with compound 4, an inhibitor of ROCK1 identified through high-throughput screening, systematic exploration of SAR, and application of structure-based design, led to potent and selective ROCK inhibitors. Compound 37 represents significant improvements in inhibition potency, kinase selectivity, and CYP inhibition and possesses pharmacokinetics suitable for in vivo experimentation.

Selective inhibitors of rock protein kinase and uses thereof

Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory,